New hope for hard-to-treat colon cancer: targeted drug duo shows promise
NCT ID NCT06959589
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study is testing two new drug combinations for people with a specific genetic mutation (KRAS G12C) in advanced colorectal cancer that has spread. One group gets the drugs as their first treatment, and another group gets them after standard treatment stops working. The goal is to see if these combinations can shrink tumors better than current options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.